Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to -$2.2 million.

  • Mirum Pharmaceuticals' Cash from Investing Activities rose 87.65% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.3 million, marking a year-over-year increase of 73.78%. This contributed to the annual value of -$90.1 million for FY2024, which is 15.93% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Cash from Investing Activities stood at -$2.2 million, which was up 66.25% from -$6.6 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $108.0 million during Q4 2021, with a 5-year trough of -$182.8 million in Q3 2023.
  • Its 3-year average for Cash from Investing Activities is -$20.2 million, with a median of -$2.2 million in 2025.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Cash from Investing Activities skyrocketed by 2,284.05% in 2021 and then tumbled by 124,007.69% in 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at $108.0 million in 2021, then plummeted by 75.23% to $26.8 million in 2022, then tumbled by 107.47% to -$2.0 million in 2023, then spiked by 132.05% to $641,000 in 2024, then surged by 87.65% to -$2.2 million in 2025.
  • Its Cash from Investing Activities stands at -$2.2 million for Q3 2025, versus -$6.6 million for Q2 2025 and -$16.1 million for Q1 2025.